Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy

被引：3

作者：

Siefker-Radtke, A. O. ^{[1
]}

Loriot, Y. ^{[2
]}

Necchi, A. ^{[3
]}

Huddart, R. A. ^{[4
]}

Burgess, E. F. ^{[5
]}

Rezazadeh, A. ^{[6
]}

O'Hagan, A. ^{[7
]}

De Porre, P. ^{[8
]}

Avadhani, A. ^{[9
]}

Monga, M. ^{[7
]}

Cherkas, Y. ^{[7
]}

Moy, C. H. ^{[7
]}

Santiago-Walker, A. ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol Dept, Houston, TX 77030 USA

[2] Univ Paris Saclay, Univ Paris Sud, Inst Gustave Roussy, Villejuif, France

[3] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[4] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England

[5] Levine Canc Inst, Med Oncol, Charlotte, NC USA

[6] Norton Healthcare, Dept Genitourinary Med Oncol, Louisville, KY USA

[7] Janssen Res & Dev, Spring House, PA USA

[8] Janssen Res & Dev, Beerse, Belgium

[9] Janssen Res & Dev, Res & Dev, Spring House, PA USA

来源：

关键词：

D O I：

10.1016/j.annonc.2020.08.823

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

751P

引用

页码：S584 / S584

页数：1